Blockade of the Programmed Death-1 Pathway Restores Sarcoidosis CD4 ⁺ T-Cell Proliferative Capacity

Abstract

Analogous to the effects in other chronic lung diseases, these findings demonstrate that the PD-1 pathway is an important contributor to sarcoidosis CD4(+) T-cell proliferative capacity and clinical outcome. Blockade of the PD-1 pathway may be a viable therapeutic target to optimize clinical outcomes.